A new experimental treatment for children with a hard-to-treat form of epilepsy is safe and can reduce seizures dramatically, helping them lead much healthier and happier lives, according to the findings of a UCL (University College London) and Great Ormond Street Hospital-led international clinical trial. In a paper published in The New England Journal of Medicine, researchers found that children with Dravet syndrome had up to 91% fewer seizures while being regularly administered a new medication called zorevunersen.
The results also show, for the first time, the potential to reduce the impact of the condition on a child’s mental processes and behavior. The children’s quality of life improved over a three-year period and most of the treatment’s side effects were mild.
Dravet syndrome is a devastating genetic condition that causes frequent, hard-to-control seizures and long-term neurodevelopmental impairment. The condition also causes feeding difficulties, movement problems and has a high risk of premature death. Current treatments fail to control seizures in most patients and there are no approved medicines that address the condition’s devastating cognitive and behavioral impacts.









